Preparation method and content detection method of compound

The compound of formula I was prepared and isolated and purified by high-temperature destruction of vidraglitine and pharmaceutical excipients, combined with high-performance liquid chromatography detection, the detection problem of unknown impurity RRT0.92 in metformin vidraglitine tablets was solved, and the accuracy of drug quality was achieved Improve control and medication safety.

CN118994162APending Publication Date: 2024-11-22YANGTZE RIVER PHARM GRP CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310553408.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-17
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The existing metformin viragliptin tablets contain unknown impurity RRT0.92, which affects drug quality control and lacks effective detection methods, making it difficult to ensure drug safety and product quality.

Method used

The compound of formula I was prepared and isolated by destroying viragliptin and pharmaceutical excipients at high temperature, and its content was detected by high performance liquid chromatography-UV absorption detector to ensure quality control in the preparation.

Benefits of technology

Accurate detection and quality control of the compounds of formula I of metformin viragliptin tablets is achieved, which improves the safety of medication, reduces the possibility of side reactions, and ensures the stability of the formulation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118994162A_ABST
    Figure CN118994162A_ABST
Patent Text Reader

Abstract

The invention provides a preparation method and a content detection method of a compound as shown in a formula I. The compound as shown in the formula I can be obtained by breaking vildagliptin and pharmaceutic adjuvants at high temperature and separating and purifying through preparative liquid chromatography, and the purity is relatively high; by adopting a high performance liquid chromatography-ultraviolet absorption detector, the main component peak and the compound shown in the formula I in the vildagliptin-containing preparation can be effectively separated, the content of the compound shown in the formula I in the vildagliptin-containing preparation can be accurately detected, the quality of the vildagliptin-containing preparation can be controlled, the risk possibly caused by the fact that the compound shown in the formula I is not detected or is not accurately detected can be avoided, and the quality of the vildagliptin-containing preparation can be ensured. Therefore, the medication safety of the vildagliptin preparation is ensured, and the possibility of side reactions caused by medication of patients is reduced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the technical field of drug analysis, and in particular to a method for preparing a compound and a method for detecting its content. Background Art

[0002] Metformin vildagliptin tablets are compound preparations, whose components are metformin hydrochloride (1,1-dimethylbiguanide hydrochloride) and vildagliptin (1-[(3-hydroxy-adamantan-1-yl-amino)-acetyl]-pyrrolidino-2(S)-nitrile). They are used in combination with diet and exercise therapy for adult type 2 diabetes patients whose blood sugar cannot be controlled after the maximum tolerated dose of metformin monotherapy or who are receiving vildagliptin combined with metformin. Of the two components, the chemical properties of the metformin hydrochloride component are relatively stable, while the chemical properties of vildagliptin are unstable, and its impurities increase significantly under high temperature, acid, alkali, and oxidative damage conditions. Therefore, special attention should be paid to the degradation impurities of the vildagliptin component in compound preparations.

[0003] In the import registration standard for metformin vildagliptin tablets (JX20160356), vildagliptin (C 17 H 25 N3O2, 303.40) degraded impurity 202-01 (amide, C 17 H 27 N3O3, 321.41), 207-01 (diketopiperazine, C 17 H 24 N2O3, 304.38) and 209-01 (cyclic amidine, C 17 H 25 N3O2, 303.40) with the limits being: impurity 202-01 ≤ 2.0% of the labeled amount, impurity 209-01 ≤ 1.0% of the labeled amount, impurity 207-01 ≤ 1.0% of the labeled amount, other individual impurities ≤ 0.2% of the labeled amount, and total impurities of vildagliptin ≤ 3.5% of the labeled amount.

[0004]

[0005] This application conducts a stability study on metformin vildagliptin tablets. During the accelerated 6-month (40±2°C, 75%±2%RH) study, in addition to the vildagliptin degradation impurities 202-01, 207-01, and 209-01 mentioned in the import registration standard JX20160356 showing an increasing trend, it is also found that an unknown impurity (herein, uniformly referred to as RRT0.92, i.e., a compound of formula I) at a relative retention time (RRT) of about 0.92 shows an increasing trend, and the impurity has not yet been disclosed in quality standards, impurity preparation, patents or articles. In order to accurately control the product quality of metformin vildagliptin tablets, it is necessary to develop a preparation method that can separate the compound of formula I that affects the quality of the drug, and a detection method that can accurately determine its content, so as to achieve accurate and effective control of the quality of metformin vildagliptin drugs, thereby ensuring the drug safety of metformin vildagliptin, which has great research significance. Summary of the invention

[0006] The purpose of the present application is to provide a compound of formula I and a preparation method and a content detection method thereof, so as to prepare the compound of formula I and determine the content of the compound in a preparation containing vildagliptin, thereby solving the problems of scarcity of detection methods for related substances in preparations containing vildagliptin including the compound of formula I and the drug safety of preparations containing vildagliptin.

[0007] The first aspect of the present application provides a compound of formula I, whose chemical structure is shown below:

[0008]

[0009] Preferably, the compound of formula I is contained in a preparation containing vildagliptin and a binder, the mass ratio of the binder to the vildagliptin is (0.05-20):1; the binder is selected from at least one of hydroxypropyl cellulose, hydroxyethyl cellulose or hydroxypropyl methyl cellulose.

[0010] The second aspect of the present application provides a method for preparing the compound of formula I of the first aspect of the present application, comprising the following steps: the compound of formula I is produced by a compound synthesis process or high temperature destruction of vildagliptin and a pharmaceutical excipient; preferably, the pharmaceutical excipient comprises a binder, and the binder is selected from at least one of hydroxypropyl cellulose, hydroxyethyl cellulose or hydroxypropyl methyl cellulose; preferably, the mass ratio of the binder to the vildagliptin is (0.05-20):1;

[0011] Preferably, the compound of formula I is produced by high temperature destruction of vildagliptin and pharmaceutical excipients, comprising:

[0012] (1) mixing vildagliptin and pharmaceutical excipients, and destroying them at a temperature ≥ 30° C. to obtain a high temperature product;

[0013] (2) taking the high temperature product and separating and purifying it to obtain the compound of formula I.

[0014] The third aspect of the present application provides a method for detecting related substances in a vildagliptin preparation, the detection method comprising:

[0015] A water-acetonitrile-phosphoric acid solution with a volume ratio of (85-95):(8-12):(0.08-0.12) is used as a solvent to prepare a test solution of a preparation containing vildagliptin to be tested, wherein the concentration C1 of vildagliptin in the test solution is 0.3-0.7 mg / mL; preferably, the method for preparing the test solution comprises: taking the preparation containing vildagliptin to be tested, adding the solvent to perform ultrasound, centrifuging and filtering to obtain the test solution;

[0016] The content of related substances in the vildagliptin-containing preparation is determined by high performance liquid chromatography-ultraviolet absorption detector; the related substances include the aforementioned compound of formula I;

[0017] The chromatographic conditions of the high performance liquid chromatography include:

[0018] Chromatographic column: octadecylsilane bonded silica gel chromatographic column;

[0019] Mobile phase: Phase A is phosphate buffered saline solution containing ammonium hexafluorophosphate-water, wherein the phosphate concentration in the phosphate buffered saline solution containing ammonium hexafluorophosphate is 1.5-2 mg / mL, the ammonium hexafluorophosphate concentration is 5-12 mg / mL, and the pH is 2.3-3.5; Phase B is phosphate buffered saline solution-acetonitrile, wherein the phosphate concentration in the phosphate buffered saline solution is 1.5-2 mg / mL; gradient elution;

[0020] Preferably, in the phase A, the volume ratio of the phosphate buffer solution containing ammonium hexafluorophosphate to water is (35-45):(55-65), and in the phase B, the volume ratio of the phosphate buffer solution to acetonitrile is (35-45):(55-65);

[0021] The chromatogram of the test solution is obtained by detection, and the chromatographic peak area of ​​the compound of formula I is obtained, and the content of the compound of formula I in the vildagliptin-containing preparation to be tested is calculated;

[0022] Preferably, in the phase A, in the phosphate buffered saline solution containing ammonium hexafluorophosphate, the phosphate concentration is 1.6-1.8 mg / mL, the ammonium hexafluorophosphate concentration is 7-9 mg / mL, the pH is 2.9-3.1, and the phosphate is selected from anhydrous potassium dihydrogen phosphate or anhydrous sodium dihydrogen phosphate; in the phase B, the phosphate concentration is 1.6-1.8 mg / mL, and the phosphate is selected from anhydrous potassium dihydrogen phosphate or anhydrous sodium dihydrogen phosphate.

[0023] The present application provides a method for preparing a compound of formula I and a method for detecting its content. It is found through screening that the compound of formula I is present in a preparation containing at least one of vildagliptin and hydroxypropyl cellulose, hydroxyethyl cellulose or hydroxypropyl methyl cellulose, while the raw material itself does not contain it, and it is found that the amount of the compound generated is extremely related to the temperature. Therefore, the compound can not only identify the types of excipients contained in the preparation, but also monitor the preparation process and the temperature of storage. The preparation process of the compound of formula I provided in the present application can destroy vildagliptin and specific pharmaceutical excipients by high temperature, and separate and purify by preparative liquid chromatography to obtain the compound of formula I, and the purity is high. The main component peak and the compound of formula I in the preparation containing vildagliptin can be effectively separated by high performance liquid chromatography-ultraviolet absorption detector, and the content of the compound of formula I in the preparation containing vildagliptin can be accurately detected, so as to realize the control of the quality of the preparation containing vildagliptin, avoid the risk that the compound of formula I is not detected or inaccurately detected, thereby ensuring the safety of the medication of the vildagliptin preparation and reducing the possibility of adverse reactions to the medication of the patient. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] In order to more clearly illustrate the technical solutions in the embodiments of the present application, the drawings required for use in the description of the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present application, and a person skilled in the art can also obtain other embodiments based on these drawings.

[0025] Figure 1 In the test for determining the source of the compound of formula I, the chromatograms of the solutions of samples ①-⑦ after being destroyed at 60°C for 30 days;

[0026] Figure 2A It is the ultraviolet full wavelength scanning spectrum of the compound of formula I in the generic preparation;

[0027] Figure 2B is the UV full wavelength scanning spectrum of the compound of formula I in the reference preparation;

[0028] Figure 3 is the mass spectrum of the compound of formula I. DETAILED DESCRIPTION

[0029] The following will be combined with the drawings in the embodiments of the present application to clearly and completely describe the technical solutions in the embodiments of the present application. Obviously, the described embodiments are only part of the embodiments of the present application, not all of the embodiments. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in this field based on the present application belong to the scope of protection of the present application.

[0030] The first aspect of the present application provides a compound of formula I, whose chemical structure is as follows:

[0031]

[0032] Preferably, the compound of formula I is contained in a preparation containing vildagliptin and a binder, the mass ratio of the binder to the vildagliptin is (0.05-20):1; the binder is selected from at least one of hydroxypropyl cellulose, hydroxyethyl cellulose or hydroxypropyl methyl cellulose.

[0033] Preferably, the content of the compound of formula I accounts for ≤0.2% of the preparation.

[0034] The second aspect of the present application provides a method for preparing the compound of formula I of the first aspect of the present application, comprising the following steps: the compound of formula I is produced by a compound synthesis process or high temperature destruction of vildagliptin and a pharmaceutical excipient; preferably, the pharmaceutical excipient comprises a binder, and the binder is selected from at least one of hydroxypropyl cellulose, hydroxyethyl cellulose or hydroxypropyl methyl cellulose; preferably, the mass ratio of the binder to the vildagliptin is (0.05-20):1;

[0035] Preferably, the compound of formula I is produced by high temperature destruction of vildagliptin and pharmaceutical excipients, comprising:

[0036] (1) mixing vildagliptin and pharmaceutical excipients, and destroying them at a temperature ≥ 30° C. to obtain a high temperature product;

[0037] (2) taking the high temperature product and separating and purifying it to obtain the compound of formula I.

[0038] The present application has no particular limitation on the longest high-temperature damage time, as long as the purpose of the present application can be achieved.

[0039] Preferably, the temperature of the high temperature destruction is 30-100°C, and the time of the high temperature destruction is at least 1 day. More preferably, the temperature of the high temperature destruction is 60-100°C, and the time of the high temperature destruction is at least 3 days. Further preferably, the time of the high temperature destruction is 3-180 days. For example, the temperature of the high temperature destruction can be 30°C, 40°C, 50°C, 60°C, 70°C, 80°C, 90°C, 100°C, etc.

[0040] The present application does not limit the method of high-temperature destruction, as long as the purpose of the present application can be achieved. For example, a constant temperature drying oven can be used for high-temperature destruction.

[0041] The compound of formula I prepared by the preparation method of the present application has a high purity, which can be as high as 95% or more.

[0042] In some embodiments of the second aspect of the present application, the pharmaceutical excipients further include at least one of a filler, a disintegrant, a lubricant or a coating agent; the filler is selected from at least one of microcrystalline cellulose, starch, sucrose, glucose, lactose, corn syrup, sorbitol, dextrin, mannitol, powdered cellulose, polysaccharide or gelatin; the disintegrant is selected from at least one of starch, clay, sodium carboxymethyl cellulose, alginate, gum, cross-linked polyvinyl pyrrolidone or cross-linked calcium carboxymethyl cellulose; the lubricant is selected from at least one of magnesium stearate, colloidal silicon dioxide, magnesium trisilicate, talc, aluminum stearate, magnesium oxide, magnesium carbonate, calcium carbonate, stearic acid, calcium stearate or micro-powdered silica gel; the coating agent is selected from at least one of a sugar coating powder, a film coating powder or an enteric coating powder.

[0043] The sugar coating powder described in the present application includes one or more of syrup, talcum powder, glue, pigment, etc. The film coating powder described in the present application refers to a premix obtained by mixing various ingredients after pretreatment; its materials include one or more of hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPC), ethyl cellulose (EC), acrylic resin VI, polyethylene glycol, glycerol, propylene glycol, triethyl citrate, triacetin, acetylated monoglyceride, phthalate, polyvinyl pyrrolidone (PVP), etc.; preferably, it is a gastric soluble film coating powder, such as Opadry premix (containing a mixture of hydroxypropyl methylcellulose and polyethylene glycol). The enteric coating powder described in the present application includes one or more of shellac, cellulose acetate phthalate (CAP), hydroxypropyl methylcellulose phthalate (HPMCP), polyvinyl acetate phthalate (PVAP), acrylic resin polymers, etc.

[0044] In some embodiments of the second aspect of the present application, the separation and purification method in step (2) includes: a preparative liquid chromatography separation and purification method, comprising the steps of:

[0045] S1. Take the high temperature product, dissolve it in a mixture of acetonitrile and water in a volume ratio of (1-3): (7-9), and separate it for the first time by preparative liquid chromatography. The chromatographic conditions include:

[0046] Preparative chromatographic column: octadecylsilane bonded silica gel chromatographic column;

[0047] Mobile phase: Phase A is 0.05-0.3% glacial acetic acid aqueous solution, and phase B is acetonitrile or methanol; use a volume fraction of 80-90% phase A and 10-20% phase B, and elute isocratically; the detection wavelength is 205-380nm, and the effluent of the target peak is collected to obtain fraction I;

[0048] Preferably, the effluent of the target peak is an effluent of any other wavelength except 205-215 nm;

[0049] S2. Take the fraction I and separate it by preparative liquid chromatography for the Nth time, and the chromatographic conditions include:

[0050] Preparative chromatographic column: octadecylsilane bonded silica gel chromatographic column;

[0051] Mobile phase: phase A is 0.05-0.3% glacial acetic acid aqueous solution, phase B is acetonitrile or methanol; gradient elution is used; detection wavelength is 205-380nm, the effluent of the target peak is collected to obtain fraction N, and dried to obtain the compound of formula I, wherein N≥0, preferably, N≥1;

[0052] Preferably, the effluent of the target peak is an effluent of any wavelength except 205-215nm. More preferably, the effluent of the target peak may be an effluent of wavelengths such as 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380nm. More preferably, any wavelength other than 205-215nm may be 370-380nm. Further preferably, any wavelength other than 205-215nm may be 374±2nm.

[0053] Preferably, the elution procedure is:

[0054]

[0055] More preferably, the elution procedure is:

[0056]

[0057] The inventors of the present application have found in their research that when N≥1, the purity of the compound represented by formula I can be as high as over 95%.

[0058] In some embodiments of the second aspect of the present application, the step S1 also includes: flow rate: 80-120mL / min; and / or, column temperature: 30-45°C; and / or, the effluent of the target peak is an effluent with a wavelength of 370-380nm; the step S2 also includes: flow rate: 80-120mL / min; and / or, column temperature: 30-45°C; and / or, the effluent of the target peak is an effluent with a wavelength of 370-380nm.

[0059] Because vildagliptin has maximum absorption at a wavelength of 210 ± 5nm. Therefore, the present application collects effluents of wavelengths other than 210 ± 5nm, so that it can be ensured that fractions I and fractions N do not co-elute with vildagliptin, avoiding the interference of vildagliptin. Especially when ensuring that vildagliptin has no absorption at 374 ± 2nm and compound I is the maximum absorption here, it is preferred to collect the effluent of the target peak as the effluent of 374 ± 2nm wavelength as the fraction of compound I. The mobile phase system ratio of the present application: phase A is 0.05-0.3% glacial acetic acid aqueous solution, and phase B is acetonitrile or methanol, which also ensures that compound I can be eluted at wavelengths other than 210 ± 5nm, while ensuring that vildagliptin and compound I do not co-elute.

[0060] The high temperature product described in the present application can be dissolved in the mixed solution. Preferably, the ratio of the mass of the high temperature product to the volume of the mixed solution is 10-200:1 (mg / mL).

[0061] The present application has no particular limitation on the drying method, as long as the purpose of the present application can be achieved. For example, evaporation, vacuum drying, freeze drying and the like can be adopted, and freeze drying is preferred.

[0062] The third aspect of the present application provides a method for detecting related substances in a vildagliptin preparation, wherein the structural formula of vildagliptin is as follows:

[0063]

[0064] The detection method comprises:

[0065] A water-acetonitrile-phosphoric acid solution with a volume ratio of (85-95):(8-12):(0.08-0.12) is used as a solvent to prepare a test solution of a preparation containing vildagliptin to be tested, wherein the concentration C1 of vildagliptin in the test solution is 0.3-0.7 mg / mL; preferably, the method for preparing the test solution comprises: taking the preparation containing vildagliptin to be tested, adding the solvent to perform ultrasound, centrifuging and filtering to obtain the test solution;

[0066] The content of the compound of formula I in the vildagliptin-containing preparation is determined by high performance liquid chromatography-ultraviolet absorption detector; the related substances include the aforementioned compound of formula I;

[0067] The chromatographic conditions of the high performance liquid chromatography include:

[0068] Chromatographic column: octadecylsilane bonded silica gel chromatographic column;

[0069] Mobile phase: Phase A is phosphate buffered saline solution containing ammonium hexafluorophosphate-water, wherein the phosphate concentration in the phosphate buffered saline solution containing ammonium hexafluorophosphate is 1.5-2 mg / mL, the ammonium hexafluorophosphate concentration is 5-12 mg / mL, and the pH is 2.3-3.5; Phase B is phosphate buffered saline solution-acetonitrile, wherein the phosphate concentration in the phosphate buffered saline solution is 1.5-2 mg / mL; gradient elution;

[0070] Preferably, in the phase A, the volume ratio of the phosphate buffer solution containing ammonium hexafluorophosphate to water is (35-45):(55-65), and in the phase B, the volume ratio of the phosphate buffer solution to acetonitrile is (35-45):(55-65);

[0071] The chromatogram of the test solution is obtained by detection, and the chromatographic peak area of ​​the compound of formula I is obtained, and the content of the compound of formula I in the vildagliptin-containing preparation to be tested is calculated;

[0072] Preferably, in the phase A, in the phosphate buffered saline solution containing ammonium hexafluorophosphate, the phosphate concentration is 1.6-1.8 mg / mL, the ammonium hexafluorophosphate concentration is 7-9 mg / mL, the pH is 2.9-3.1, and the phosphate is selected from anhydrous potassium dihydrogen phosphate or anhydrous sodium dihydrogen phosphate; in the phase B, the phosphate concentration is 1.6-1.8 mg / mL, and the phosphate is selected from anhydrous potassium dihydrogen phosphate or anhydrous sodium dihydrogen phosphate.

[0073] The present application does not limit the conditions for ultrasound, as long as the purpose of the present application can be achieved. Exemplarily, the conditions for ultrasound include: ultrasound temperature: 2-30°C, ultrasound time: greater than 30 minutes (the metformin vildagliptin tablets will only disintegrate completely if the ultrasound time is greater than 30 minutes).

[0074] The present application does not limit the filtering method as long as the purpose of the present application can be achieved. For example, a 0.22-0.45 μm filter membrane can be used for filtering.

[0075] In some embodiments of the third aspect of the present application, the chromatographic conditions further include:

[0076] Column temperature: 35-45°C; and / or, flow rate: 0.6-0.9 mL / min; and / or, injection volume V1: 5-20 μL; and / or, detection wavelength: 210±5 nm, 370-380 nm.

[0077] By analyzing the compound of formula I through the detection method of the present application, accurate determination of the content of the compound of formula I can be achieved.

[0078] The vildagliptin-containing preparation described in the present application is selected from metformin-vildagliptin tablets and vildagliptin tablets.

[0079] In the present application, the inventors have found that the gradient elution using the elution procedure described in the present application can achieve good separation of the compound of formula I and the main component in metformin vildagliptin.

[0080] In some embodiments of the third aspect of the present application, the elution procedure of the gradient elution is:

[0081]

[0082] In some embodiments of the third aspect of the present application, the content of the compound of formula I in the metformin vildagliptin preparation to be tested is calculated using the principal component self-control method or the principal component self-control method with a correction factor; the correction factor is obtained by the following method:

[0083] Using a water-acetonitrile-phosphoric acid solution with a volume ratio of (85-95):(8-12):(0.08-0.12) as a solvent, 5-12 reference solutions containing vildagliptin and the compound of formula I with known concentrations were prepared; wherein the concentration of vildagliptin was 0.15-2.2 μg / mL, and the concentration of the compound of formula I was 0.22-5.5 μg / mL;

[0084] The reference solution was detected by high performance liquid chromatography-ultraviolet absorption detector, and the chromatogram of each reference solution was obtained under the same chromatographic conditions as the detection method of the related substances of the aforementioned vildagliptin preparation, and the chromatographic peak areas of vildagliptin and the compound of formula I were obtained;

[0085] With the peak area as the ordinate and the concentration as the abscissa, the standard curves of vildagliptin and the compound of formula I were established respectively to obtain the linear slopes of vildagliptin and the compound of formula I;

[0086] According to the correction factor=linear slope of vildagliptin / linear slope of the compound of formula I, the correction factor f of the compound of formula I is obtained.

[0087] The present application does not particularly limit the number of the reference solution, as long as the purpose of the present application can be achieved. For example, 5-12 reference mixed solutions of vildagliptin and the compound of formula I can be prepared, or 5-12 vildagliptin reference solutions and 5-12 reference solutions of the compound of formula I can be prepared separately.

[0088] In some embodiments of the third aspect of the present application, the relative retention time of the compound of formula I relative to vildagliptin is 0.92±0.05.

[0089] The reagents and drugs involved in the following examples, unless otherwise specified, can all be commercially available or obtained according to methods known in the art. In the mobile phase of the examples, acetonitrile is chromatographically pure acetonitrile; in the detection of the reference solution and the test solution in the examples, a blank solution of the solvent used is set as a blank control, which is common knowledge in the art and will not be elaborated in this application.

[0090] Determination of the source of RRT0.92

[0091] Q1. Take sample a: Metformin hydrochloride + vildagliptin raw materials in the ratio of 850mg:50mg, sample b: Metformin hydrochloride 850mg, hydroxypropyl cellulose 75.00mg, microcrystalline cellulose 40.00mg, magnesium stearate 5.00mg, film coating premix (gastric soluble) 40.8mg, sample c: vildagliptin 50mg, hydroxypropyl cellulose 75.00mg, microcrystalline cellulose 40.00mg, magnesium stearate 5.00mg, film coating premix (gastric soluble) 40.8mg. The above three samples were placed at a high temperature of 60℃ for 30 days.

[0092] Preparation of test solution: Take appropriate amount of the above three samples after being placed at high temperature, place them in 100mL volumetric flasks, add about 20mL of solvent water-acetonitrile-phosphoric acid (90:10:0.1), disintegrate completely by ultrasonication in ice water bath, let it reach room temperature, dilute to scale with solvent water-acetonitrile-phosphoric acid (90:10:0.1), shake well, and prepare solutions containing about 0.5mg / mL of vildagliptin in samples a and c and about 8.5mg / mL of metformin in sample b. Take 10mL of each and centrifuge at 10000rpm for 10min, take the supernatant and filter it with 0.45μm nylon filter membrane, discard 3mL of primary filtrate, take the subsequent filtrate as the test solution.

[0093] The test solutions of the above samples ac were tested by high performance liquid chromatography-ultraviolet absorption detector, and the chromatographic conditions and detection conditions included:

[0094] Column: ACE Excel 3Super C18, 4.6×250 mm, 3 μm;

[0095] Mobile phase: Phase A is phosphate buffered saline solution containing ammonium hexafluorophosphate-water, the volume ratio is 40:60, in the phosphate buffered saline solution containing ammonium hexafluorophosphate, the phosphate is anhydrous potassium dihydrogen phosphate, the concentration is 1.7 mg / mL, the concentration of ammonium hexafluorophosphate is 8 mg / mL, and the pH is 3.0; Phase B is phosphate buffered saline solution-acetonitrile, the volume ratio is 40:60, in the phosphate buffered saline solution, the phosphate is anhydrous potassium dihydrogen phosphate, the concentration is 1.7 mg / mL; column temperature: 40°C; flow rate: 0.8 mL / min; injection volume V1: 10 μL; the elution program of gradient elution is as follows:

[0096]

[0097] Detection wavelength: 210nm, 374nm.

[0098] After testing, it was confirmed that only sample c produced RRT0.92, so the impurity was identified as a vildagliptin-related degradation impurity.

[0099] Q2. Take samples ① 850 mg of metformin hydrochloride, 50 mg of vildagliptin, 75.00 mg of hydroxypropyl cellulose, 40.00 mg of microcrystalline cellulose, 5.00 mg of magnesium stearate, and 40.8 mg of film-coating premix (gastric soluble), sample ② 50 mg of vildagliptin and 40.00 mg of microcrystalline cellulose, sample ③ 50 mg of vildagliptin and 40.8 mg of film-coating premix (gastric soluble), sample ④ 850 mg of metformin hydrochloride, 50 mg of vildagliptin, 115.00 mg of hydroxypropyl cellulose, 5.00 mg of magnesium stearate, and 40.8 mg of film-coating premix (gastric soluble), sample ⑤ 50 mg of vildagliptin and 75.00 mg of hydroxypropyl cellulose, sample ⑥ 50 mg of vildagliptin and 40.00 mg of microcrystalline cellulose, sample ⑦ 50 mg of vildagliptin, and destroy them at 60°C for 30 days.

[0100] Preparation of the sample solution to be tested: Take appropriate amounts of the above samples ①-⑦ destroyed at 60°C for 30 days, place them in 100mL volumetric flasks, add 20mL of water-acetonitrile-phosphoric acid with a volume ratio of 90:10:0.1, and completely disintegrate by ultrasonication in an ice-water bath. After bringing to room temperature, dilute to scale with water-acetonitrile-phosphoric acid with a volume ratio of 90:10:0.1, shake well, and the concentration of vildagliptin in each sample solution prepared is about 0.5mg / mL. Take 10mL of each sample solution, centrifuge at 10000rpm for 10min, take the supernatant and filter it with a 0.45μm nylon filter membrane, discard 3mL of the initial filtrate, take the subsequent filtrate, and obtain each sample solution to be tested.

[0101] The sample solutions of the above samples ①-⑦ are subjected to high performance liquid chromatography-ultraviolet absorption detector detection, and the chromatographic conditions and detection conditions are the same as those of the above samples a, b, and c;

[0102] The chromatogram of each sample solution under the detection wavelength of 374nm is as follows: Figure 1 As shown, according to Figure 1 It can be seen that sample ①, sample ④, and sample ⑤ all produced RRT0.92. Based on sample ⑤, it was confirmed that the impurity was a related degradation impurity of vildagliptin and hydroxypropyl cellulose.

[0103] Determination of the Maximum Absorption Wavelength of RRT0.92

[0104] Generic preparation: metformin hydrochloride 850 mg, vildagliptin 50 mg, hydroxypropyl cellulose 75.00 mg, microcrystalline cellulose 40.00 mg, magnesium stearate 5.00 mg, film coating premix (gastric soluble) 40.8 mg. Mix metformin hydrochloride, hydroxypropyl cellulose and microcrystalline cellulose, add water, and prepare metformin granules by wet method; mix metformin granules with vildagliptin, add magnesium stearate, press into tablets, and coat with film coating premix (gastric soluble).

[0105] Reference preparation: metformin hydrochloride 850 mg, vildagliptin 50 mg, hydroxypropyl cellulose 84.00 mg, magnesium stearate 8.9 mg, film coating premix (gastric soluble) 39.7 mg, melt-prepared according to the prescription in patent 200680036174.7. For the melt-preparation method, see Example 1B of the patent.

[0106] Take the generic preparation and the reference preparation respectively, destroy them at 60°C for 30 days, then place them in 100mL volumetric flasks respectively, add 20mL of water-acetonitrile-phosphoric acid with a volume ratio of 90:10:0.1, and completely disintegrate them by ultrasonication in an ice-water bath. After cooling to room temperature, dilute to the scale with water-acetonitrile-phosphoric acid with a volume ratio of 90:10:0.1, shake well, take 10mL of each, centrifuge at 10000rpm for 10min, take the supernatant and filter it with a 0.45μm nylon filter membrane, discard 3mL of the initial filtrate, take the subsequent filtrate to obtain each sample solution to be tested.

[0107] Take each sample solution to be tested and perform full-wavelength ultraviolet scanning with an HPLC diode array detector to obtain the full-wavelength ultraviolet scanning spectrum of RRT0.92 in the imitation preparation as shown in Figure 2A As shown, the UV full wavelength scanning spectrum of RRT0.92 in the reference preparation is as follows Figure 2B shown; according to Figure 2A and Figure 2B It can be seen that the ultraviolet absorption spectra of RRT0.92 are the same, with maximum absorption at 200nm and 374nm, indicating that they are the same degradation impurities.

[0108] Example 1 Preparation of Compound Formula I

[0109] 10 g of vildagliptin and 1 g of pharmaceutical excipient hydroxypropyl cellulose were mixed, placed in a constant temperature drying oven, and destroyed at 100°C for 3 days to obtain a high temperature product;

[0110] The high temperature product was dissolved in a mixture of acetonitrile and water with a volume ratio of 1:9, with a concentration of 100 mg / mL, and separated for the first time by preparative liquid chromatography. The chromatographic conditions included:

[0111] Preparative column: Luna PREP C18(3), 50×250 mm, 10 μm;

[0112] Mobile phase: phase A is 0.1% glacial acetic acid aqueous solution, phase B is acetonitrile; volume fraction 85% phase A, 15% phase B, isocratic elution; flow rate: 100mL / min; column temperature: 30°C; detection wavelength: 205-380nm; the effluent of the target peak is collected as the effluent with a wavelength of 374nm to obtain fraction I;

[0113] Take the above fraction I and separate it by preparative liquid chromatography for the Nth time, wherein N=1, and the chromatographic conditions include:

[0114] Preparative column: Luna PREP C18(3), 50×250 mm, 10 μm;

[0115] Mobile phase: Phase A is 0.1% glacial acetic acid aqueous solution, phase B is acetonitrile; gradient elution is adopted, and the elution program is:

[0116]

[0117] ; Flow rate: 100mL / min; Column temperature: 30℃; Detection wavelength: 205-380nm; The effluent of the target peak was collected as the effluent with a wavelength of 374nm, and the fractions were freeze-dried in a vacuum freeze dryer to obtain RRT0.92 with a content of 96.2% (the remainder was solvent and water) and a chromatographic purity of 100%.

[0118] Electrospray ionization (ESI) was used to perform mass spectrometry (MS) analysis on RRT0.92, and the mass spectrum obtained was as follows: Figure 3 As shown in the figure, it can be seen that the first-level MS full scan in the positive ESI mode shows that the quasi-molecular ion peak [M+H]+ is m / z 303.16968, and the molecular formula of the compound is determined to be C 17 H 22 N2O3 ([M+H]+ calculated theoretical value: 303.17032); [M+H]+ ion m / z 303 by ddMS 2 The secondary MS analysis was performed in the secondary scanning mode, and the main fragment ion obtained was m / z 153.06564; the possible fragmentation pathway was proposed as follows, and its fragmentation characteristics were consistent with the expected structure:

[0119]

[0120] By homonuclear chemical shift correlation spectroscopy ( 1 H- 1 H COSY), heteronuclear single quantum correlation spectroscopy (HSQC), and heteronuclear multiple bond correlation spectroscopy (HMBC) were used to detect RRT0.92, and its carbon and hydrogen data were fully assigned, as shown in Table 1:

[0121] Table 1 1D and 2D-NMR data assignment of RRT0.92 (400 and 100 MHz, DMSO-d6)

[0122]

[0123] Note: "N / A" in Table 1 means there is no corresponding parameter.

[0124] According to the results in Table 1, the structure of RRT0.92 is further speculated and verified as follows:

[0125]

[0126] Based on the above analysis, RRT0.92 is determined: molecular formula C 17 H 22 N2O3, molecular weight 302.3682, structural formula is the structure shown in formula I:

[0127]

[0128] Obtaining the Correction Factor for Compounds of Formula I

[0129] A reference solution containing known concentrations of vildagliptin and the compound of formula I was prepared using a water-acetonitrile-phosphoric acid solution with a volume ratio of 90:10:0.1 as a solvent; wherein the concentrations of vildagliptin were 0.1961, 0.4903, 0.9805, 1.4708, and 1.9610 μg / mL, and the concentrations of the compound of formula I were 0.2412, 0.4824, 1.2060, 2.4119, 3.6179, and 4.8239 μg / mL;

[0130] Each reference solution was detected by high performance liquid chromatography-ultraviolet absorption detector, and the chromatogram of each reference solution was obtained under the following chromatographic conditions, and the chromatographic peak areas of vildagliptin and the compound of formula I were obtained;

[0131] With the peak area as the ordinate and the concentration as the abscissa, the standard curves of vildagliptin and the compound of formula I were established respectively to obtain the linear slopes of vildagliptin and the compound of formula I;

[0132] According to the correction factor = linear slope of vildagliptin / linear slope of the compound of formula I, the correction factor f of the compound of formula I is obtained, as shown in Table 2;

[0133] In this experiment, another experimenter (experimenter 2) performed the above steps simultaneously and obtained the correction factor f of the compound of formula I, as shown in Table 2, wherein the concentrations of vildagliptin were 0.1992, 0.4981, 0.9962, 1.4943, and 1.9924 μg / mL, and the concentrations of the compound of formula I were 0.2615, 0.5230, 1.3076, 2.6151, 3.9227, and 5.2302 μg / mL;

[0134] Table 2 Correction factors for compounds of formula I

[0135]

[0136] Wherein, the chromatographic conditions include:

[0137] Column: ACE Excel 3Super C18, 4.6×250 mm, 3 μm;

[0138] Mobile phase: Phase A is phosphate buffered saline solution containing ammonium hexafluorophosphate-water, the volume ratio is 40:60, in the phosphate buffered saline solution containing ammonium hexafluorophosphate, the phosphate is anhydrous potassium dihydrogen phosphate, the concentration is 1.7 mg / mL, the concentration of ammonium hexafluorophosphate is 8 mg / mL, and the pH is 3.0; Phase B is phosphate buffered saline solution-acetonitrile, the volume ratio is 40:60, in the phosphate buffered saline solution, the phosphate is anhydrous potassium dihydrogen phosphate, the concentration is 1.7 mg / mL; column temperature: 40°C; flow rate: 0.8 mL / min; injection volume V1: 10 μL; the elution program of gradient elution is as follows:

[0139]

[0140] Detection wavelength: 210nm, 374nm.

[0141] Example 2 Detection of the content of the compound of formula I

[0142] A water-acetonitrile-phosphoric acid solution with a volume ratio of 90:10:0.1 is used as a solvent, and the metformin vildagliptin preparation to be tested (a generic preparation, not prepared by melting, with the same composition and content as the generic preparation in "Determination of the maximum absorption wavelength of RRT0.92", and not destroyed) is taken, and the solvent is added for ultrasonication, and the mixture is filtered after centrifugation to obtain a test solution containing the vildagliptin preparation to be tested, wherein the concentration C1 of vildagliptin in the test solution is 0.5 mg / mL;

[0143] The test solution is detected by a high performance liquid chromatography-ultraviolet absorption detector, and a chromatogram of the test solution is obtained under the same chromatographic conditions as in the experiment of "obtaining the correction factor of the compound of formula I", and the chromatographic peak of the compound of formula I is determined according to the relative retention time RRT=0.92 of the compound of formula I relative to vildagliptin, and the chromatographic peak area of ​​the compound of formula I is obtained;

[0144] The content of the compound of formula I was calculated using the principal component self-comparison method (equivalent to a correction factor of 1.00) or the principal component self-comparison method with a correction factor of f=0.6. The results are shown in Table 3.

[0145] Example 3-6 Content Detection of Formula I Compound

[0146] The contents of the compound of formula I were obtained in the same manner as in Example 2, except that the metformin-vildagliptin preparation to be tested (generic preparation, same as in Example 2) was subjected to accelerated testing at 40°C ± 2°C and 75 ± 5% relative humidity (RH) for 1 month, 2 months, 3 months, and 6 months, respectively. The results are shown in Table 3.

[0147] Example 7-10 Content Detection of Formula I Compound

[0148] The contents of the compound of formula I were obtained in the same manner as in Example 2, except that the metformin-vildagliptin preparation to be tested (generic preparation, same as in Example 2) was subjected to long-term tests at 30°C ± 2°C, 65 ± 5% RH for 3 months, 6 months, 9 months, and 12 months, respectively. The results are shown in Table 3.

[0149] Example 11 Detection of the content of the compound of formula I

[0150] The contents of the compound of formula I were obtained in the same manner as in Example 2, except that the metformin-vildagliptin preparation to be tested was prepared by high-temperature melting of a reference preparation (the composition and content were the same as the reference preparation in "Determination of the maximum absorption wavelength of RRT0.92", and were not destroyed). The results are shown in Table 3.

[0151] Example 12-13 Content Detection of Formula I Compound

[0152] The contents of the compound of formula I were obtained in the same manner as in Example 2, except that the metformin-vildagliptin preparation to be tested (reference preparation, same as in Example 11) was subjected to accelerated testing at 40°C±0°C and 75±5% RH for 3 months and 6 months, respectively. The results are shown in Table 3.

[0153] Example 14-15 Content Detection of Formula I Compound

[0154] The contents of the compound of formula I were obtained in the same manner as in Example 2, except that the metformin-vildagliptin preparation to be tested (reference preparation, same as in Example 11) was subjected to long-term tests at 30°C±2°C and RH65±5%RH for 3 months and 12 months, respectively. The results are shown in Table 3.

[0155] Example 16 Detection of the content of the compound of formula I

[0156] The content of the compound of formula I was obtained in the same manner as in Example 2, except that the metformin-vildagliptin preparation to be tested (reference preparation, same as Example 11) was subjected to the influencing factor test at 60° C. for 30 days. The results are shown in Table 3.

[0157] Example 17-19 Content Detection of Formula I Compound

[0158] The contents of the compound of formula I were obtained in the same manner as in Example 2, except that the metformin-vildagliptin preparation to be tested (generic preparation, same as in Example 2) was subjected to the influencing factor test at 60° C. for 5 days, 10 days, and 30 days, respectively. The results are shown in Table 3.

[0159] According to the results in Table 3, in the present application, the content of the compound of formula I in the present application can be obtained by using the principal component self-reference method. Furthermore, the content of the compound of formula I in the present application can be obtained more accurately by using the principal component self-reference method with a correction factor.

[0160] Stability test

[0161] The factors affecting the stability of metformin vildagliptin tablets were investigated by influencing factor tests, and the long-term stability of metformin vildagliptin tablets was investigated by accelerated tests and long-term tests. The content results of the compound of formula I are shown in Table 3. As can be seen from Table 3, under the conditions of influencing factor test 60°C, accelerated test 40°C±2°C, 75±5%RH and long-term test 30°C±2°C, 65±5%RH, the correction factor was calculated according to 1.00, and the content of the compound of formula I during the stability period exceeded the quality control limit (0.2%), and the preparation of the compound of formula I by the present application, and the correction factor f=0.60 after confirmation, the content result of the compound of formula I obtained by recalculation is more accurate. Therefore, the correction factor 0.60 is selected.

[0162] As can be seen from Table 3, according to the correction factor of 0.60, during the influencing factor test, at 60°C, the content of the compound of formula I in the generic preparation of metformin vildagliptin tablets of the present application increased with the extension of the test time, but it was lower than the quality control limit (0.2%), and the safety risk was relatively small; while the reference preparation exceeded the quality control limit, and the safety risk was relatively large.

[0163] As can be seen from Table 3, during the accelerated and long-term stability tests, the content of the compound of formula I in the generic preparation of metformin vildagliptin tablets of the present application was lower than the quality control limit (0.2%), the impurity content was relatively stable, and the safety risk was relatively small. However, as time went on, the impurity content of the reference preparation increased rapidly, especially in the accelerated test, the impurity generation of the reference preparation exceeded the quality control standard, and the safety risk was relatively large.

[0164] Table 3 Content of compound of formula I (%)

[0165]

[0166] Note: In Table 3, “ND” means not detected and “N / A” means not detected.

[0167] In summary, the present application provides a method for preparing a compound of formula I and a method for detecting its content, wherein vildagliptin and pharmaceutical excipients are destroyed at high temperature, and separated and purified by preparative liquid chromatography to obtain a compound of formula I with a purity of more than 95%; a high performance liquid chromatography-ultraviolet absorption detector can be used to effectively separate the main component peak and the compound of formula I in metformin vildagliptin tablets, and the content of the compound of formula I in metformin vildagliptin tablets can be accurately detected.

[0168] It should be noted that, in this article, the terms "comprises", "includes" or any other variations thereof are intended to cover non-exclusive inclusion, so that a process, method, article or apparatus that includes a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, article or apparatus.

[0169] Each embodiment in this specification is described in a related manner, and the same or similar parts between the embodiments can be referenced to each other, and each embodiment focuses on the differences from other embodiments.

[0170] The above description is only a preferred embodiment of the present application and is not intended to limit the protection scope of the present application. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present application are included in the protection scope of the present application.

Claims

1. A compound of formula I, whose chemical structure is as follows: Preferably, the compound of formula I is contained in a preparation containing vildagliptin and a binder, the mass ratio of the binder to the vildagliptin is (0.05-20):1; the binder is selected from at least one of hydroxypropyl cellulose, hydroxyethyl cellulose or hydroxypropyl methyl cellulose.

2. A method for preparing the compound of formula I according to claim 1, comprising the following steps: The compound of formula I is produced by a compound synthesis process or high temperature destruction of vildagliptin and pharmaceutical excipients; preferably, the pharmaceutical excipients include a binder, and the binder is selected from at least one of hydroxypropyl cellulose, hydroxyethyl cellulose or hydroxypropyl methyl cellulose; preferably, the mass ratio of the binder to the vildagliptin is (0.05-20):1; Preferably, the compound of formula I is produced by high temperature destruction of vildagliptin and pharmaceutical excipients, comprising: (1) mixing vildagliptin and pharmaceutical excipients, and destroying them at a temperature ≥ 30° C. to obtain a high temperature product; (2) taking the high temperature product and separating and purifying it to obtain the compound of formula I.

3. The preparation method according to claim 2, wherein The temperature of the high temperature destruction is 30-100°C, and the time of the high temperature destruction is at least 1 day. Preferably, the temperature of the high temperature destruction is 60-100°C, and the time of the high temperature destruction is at least 3 days.

4. The preparation method according to claim 2, wherein The pharmaceutical excipients also include at least one of a filler, a disintegrant, a lubricant or a coating agent; the filler is selected from at least one of microcrystalline cellulose, starch, sucrose, glucose, lactose, corn syrup, sorbitol, dextrin, mannitol, powdered cellulose, polysaccharide or gelatin; the disintegrant is selected from at least one of starch, clay, sodium carboxymethyl cellulose, alginate, gum, cross-linked polyvinyl pyrrolidone or cross-linked calcium carboxymethyl cellulose; the lubricant is selected from at least one of magnesium stearate, colloidal silicon dioxide, magnesium trisilicate, talc, aluminum stearate, magnesium oxide, magnesium carbonate, calcium carbonate, stearic acid, calcium stearate or micro-powdered silica gel; the coating agent is selected from at least one of sugar coating powder, film coating powder or enteric coating powder.

5. The preparation method according to any one of claims 2 to 4, wherein The separation and purification method in step (2) includes: a preparative liquid chromatography separation and purification method, comprising the steps of: S1. Take the high temperature product, dissolve it in a mixture of acetonitrile and water in a volume ratio of (1-3): (7-9), and separate it for the first time by preparative liquid chromatography. The chromatographic conditions include: Preparative chromatographic column: octadecylsilane bonded silica gel chromatographic column; Mobile phase: Phase A is 0.05-0.3% glacial acetic acid aqueous solution, and phase B is acetonitrile or methanol; use a volume fraction of 80-90% phase A and 10-20% phase B, and elute isocratically; the detection wavelength is 205-380nm, and the effluent of the target peak is collected to obtain fraction I; Preferably, the effluent of the target peak is an effluent of any other wavelength except 205-215 nm; S2. Take the fraction I and separate it by preparative liquid chromatography for the Nth time, and the chromatographic conditions include: Preparative chromatographic column: octadecylsilane bonded silica gel chromatographic column; Mobile phase: phase A is 0.05-0.3% glacial acetic acid aqueous solution, phase B is acetonitrile or methanol; gradient elution is used; detection wavelength is 205-380nm, the effluent of the target peak is collected to obtain fraction N, and dried to obtain the compound of formula I, wherein N≥0, preferably, N≥1; Preferably, the effluent of the target peak is an effluent of any other wavelength except 205-215 nm; Preferably, the elution procedure is: More preferably, the elution procedure is:

6. The preparation method according to claim 5, wherein: The step S1 also Including: flow rate: 80-120mL / min; and / or, column temperature: 30-45°C; and / or, the effluent of the target peak is an effluent with a wavelength of 370-380nm; The step S2 also Including: flow rate: 80-120mL / min; and / or, column temperature: 30-45°C; and / or, the effluent of the target peak is an effluent with a wavelength of 370-380nm.

7. A method for detecting related substances in a vildagliptin preparation, wherein: The detection method comprises: A water-acetonitrile-phosphoric acid solution with a volume ratio of (85-95):(8-12):(0.08-0.12) is used as a solvent to prepare a test solution of a preparation containing vildagliptin to be tested, wherein the concentration C1 of vildagliptin in the test solution is 0.3-0.7 mg / mL; preferably, the method for preparing the test solution comprises: taking the preparation containing vildagliptin to be tested, adding the solvent to perform ultrasound, centrifuging and filtering to obtain the test solution; The content of related substances in the vildagliptin preparation is determined by high performance liquid chromatography-ultraviolet absorption detector; the related substances include the compound of formula I as claimed in claim 1; The chromatographic conditions of the high performance liquid chromatography include: Chromatographic column: octadecylsilane bonded silica gel chromatographic column; Mobile phase: Phase A is phosphate buffered saline solution containing ammonium hexafluorophosphate-water, wherein the phosphate concentration in the phosphate buffered saline solution containing ammonium hexafluorophosphate is 1.5-2 mg / mL, the ammonium hexafluorophosphate concentration is 5-12 mg / mL, and the pH is 2.3-3.5; Phase B is phosphate buffered saline solution-acetonitrile, wherein the phosphate concentration in the phosphate buffered saline solution is 1.5-2 mg / mL; gradient elution; Preferably, in the phase A, the volume ratio of the phosphate buffer solution containing ammonium hexafluorophosphate to water is (35-45):(55-65), and in the phase B, the volume ratio of the phosphate buffer solution to acetonitrile is (35-45):(55-65); The chromatogram of the test solution is obtained by detection, and the chromatographic peak area of ​​the compound of formula I is obtained, and the content of the compound of formula I in the vildagliptin-containing preparation to be tested is calculated; Preferably, in the phase A, in the phosphate buffered saline solution containing ammonium hexafluorophosphate, the phosphate concentration is 1.6-1.8 mg / mL, the ammonium hexafluorophosphate concentration is 7-9 mg / mL, the pH is 2.9-3.1, and the phosphate is selected from anhydrous potassium dihydrogen phosphate or anhydrous sodium dihydrogen phosphate; in the phase B, the phosphate concentration is 1.6-1.8 mg / mL, and the phosphate is selected from anhydrous potassium dihydrogen phosphate or anhydrous sodium dihydrogen phosphate.

8. The detection method according to claim 7, wherein: The chromatographic conditions also include: Column temperature: 35-45°C; and / or, flow rate: 0.6-1.0 mL / min; and / or, injection volume V1: 5-20 μL; and / or, detection wavelength: 210±5 nm, 370-380 nm.

9. The detection method according to claim 7, wherein: The elution procedure of the gradient elution is:

10. The detection method according to any one of claims 7 to 9, wherein: The content of the compound of formula I in the vildagliptin-containing preparation to be tested is calculated by the principal component self-control method or the principal component self-control method with a correction factor; the correction factor is obtained by the following method: Using a water-acetonitrile-phosphoric acid solution with a volume ratio of (85-95):(8-12):(0.08-0.12) as a solvent, 5-12 reference solutions containing vildagliptin and the compound of formula I with known concentrations were prepared; wherein the concentration of vildagliptin was 0.15-2.2 μg / mL, and the concentration of the compound of formula I was 0.22-5.5 μg / mL; Using a high performance liquid chromatography-ultraviolet absorption detector to detect each reference solution, under the same chromatographic conditions as in claim 7, the chromatogram of each reference solution is detected, and the chromatographic peak areas of vildagliptin and the compound of formula I are obtained; With the peak area as the ordinate and the concentration as the abscissa, the standard curves of vildagliptin and the compound of formula I were established respectively to obtain the linear slopes of vildagliptin and the compound of formula I; According to the correction factor=linear slope of vildagliptin / linear slope of the compound of formula I, the correction factor f of the compound of formula I is obtained.